{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:39:39Z","timestamp":1776854379221,"version":"3.51.2"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s12185-023-03633-8","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T12:01:50Z","timestamp":1689163310000},"page":"647-651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma"],"prefix":"10.1007","volume":"118","author":[{"given":"Yoko","family":"Nakanishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Marumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9617-486X","authenticated-orcid":false,"given":"Masaki","family":"Ri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"9","key":"3633_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41408-022-00733-2","volume":"12","author":"SK Gill","year":"2022","unstructured":"Gill SK, Unawane R, Wang S, Ahn J, Aleman A, Siegel DS, et al. I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients. Blood Cancer J. 2022;12(9):138.","journal-title":"Blood Cancer J"},{"issue":"20","key":"3633_CR2","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","volume":"125","author":"P Moreau","year":"2015","unstructured":"Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125(20):3076\u201384.","journal-title":"Blood"},{"issue":"1","key":"3633_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"NWCJ van de Donk","year":"2018","unstructured":"van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13\u201329.","journal-title":"Blood"},{"issue":"8","key":"3633_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"7","key":"3633_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41409-018-0412-1","volume":"54","author":"A Jin","year":"2019","unstructured":"Jin A, Feng J, Wang Z, Jiang L, Hu Y, Zhao K, et al. Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed\/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2019;54(7):969\u201372.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3633_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000522669","volume":"15","author":"H Shima","year":"2022","unstructured":"Shima H, Kurosawa T, Oikawa H, Kobayashi H, Nishi E, Yamazaki F, et al. Cervical edema extending to the larynx as local cytokine release syndrome following chimeric antigen receptor T-cell therapy in a boy with refractory acute lymphoblastic leukemia. Case Rep Oncol. 2022;15(1):257\u201362.","journal-title":"Case Rep Oncol"},{"key":"3633_CR7","doi-asserted-by":"publisher","first-page":"707191","DOI":"10.3389\/fimmu.2021.707191","volume":"12","author":"C Luan","year":"2021","unstructured":"Luan C, Zhou J, Wang H, Ma X, Long Z, Cheng X, et al. Case report: local cytokine release syndrome in an acute lymphoblastic leukemia patient after treatment with chimeric antigen receptor T-cell therapy: a possible model. Lit Rev Persp Front Immunol. 2021;12:707191.","journal-title":"Lit Rev Persp Front Immunol"},{"issue":"1","key":"3633_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","volume":"5","author":"J Wei","year":"2020","unstructured":"Wei J, Liu Y, Wang C, Zhang Y, Tong C, Dai G, et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther. 2020;5(1):134.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3633_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","volume":"11","author":"D Liu","year":"2018","unstructured":"Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy. J Hematol Oncol. 2018;11(1):121.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"3633_CR10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731\u20138.","journal-title":"Nat Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03633-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03633-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03633-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T15:23:56Z","timestamp":1698679436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03633-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["3633"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03633-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Masaki Ri reports honoraria from Jansesen Pharmaceutical K.K. and research funds from Bristol-Myers Squibb K.K., Daichi Sankyo Co., Ltd., Celgene K.K., and scholarship endowments from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Ono Pharma USA, Inc., Kyowa Kirin Co., Ltd. Shigeru Kusumoto reports honoraria from Jansesen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Ono Pharma USA, Inc., and research funds from Daichi Sankyo Co., Ltd., and scholarship endowments from Chugai Pharmaceutical Co., Ltd. Shinsuke Iida reports honoraria from Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Sanofi Co., Ltd., Takeda Pharmaceutical Co., Ltd., Ono Pharma USA, Inc., Celgene K.K., and research funds from Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Sanofi Co., Ltd., Takeda Pharmaceutical Co. Ltd., Ono Pharma USA, Inc., Daichi Sankyo Co., Ltd., Abbvie GK, Novartis Pharma K.K., Otsuka Pharmaceutical K.K., Amgen Inc., Chugai Pharmaceutical Co., Ltd., Celgene K.K., Glaxo SmithKlein plc., Alexion Pharmaceuticals, Inc., Pfizer Inc., Shionogi Co., Ltd., and scholarship endowments from Chugai Pharmaceutical Co., Ltd. The other authors have nothing to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}